As laboratories face the challenge of screening many samples for SARS-CoV-2, lab managers have turned to the use of automation to address key concerns.
List view / Grid view
Filter the results
A new study has suggested that asymptomatic individuals with COVID-19 mount an efficient T-cell response that protects the host.
eBook: Revolutionise your lab with a cutting-edge bioprocess platform to drive quality and efficiency
With the right solution organisations can simplify their lab-based working, while ensuring the highest level of compliance with regulatory requirements.
Researchers have developed stem cell-derived organoids to reveal how SARS-CoV-2 interacts with lung and brain cells differently.
Between January and October 2020, scientists globally have published more than 87,000 papers about the coronavirus.
Sino Biological has developed 80+ mutant proteins covering the newest mutations identified in SARS-CoV-2 variants, such as UK's B.1.1.7, Brazil's P.1.
Using liquid chromatography/mass spectrometry, researchers have revealed no major differences in glycan structures in two prion strains.
Vito Quaranta, professor of biochemistry and pharmacology, discusses how cancerous cells adopting novel mechanisms of energy production could be sensitised to existing therapies with a focus on melanoma.
The UK Government will give £18.5 million in funding to four studies researching the causes and potential treatments of long COVID.
A study has shown the D614G mutation in the Spike protein of SARS-CoV-2 makes the coronavirus more transmissible than the original virus from China.
Using single-cell RNA sequencing, researchers have shown that interferon response is correlated with tuberculosis progression.
Comparing the original SARS-CoV-2 Spike protein with a mutated version, researchers have potentially revealed why the mutated version is dominant.
A team has revealed that viruses ‘hijack’ a molecular process in the cell, inhibiting the body’s response to viral infection.
Research has shown that ACE2 and several integrins containing SLiMs are involved in SARS-CoV-2 infection, presenting new therapeutic targets.